Publications by authors named "Robert Lapidus"
Purpose: To determine improvement in breast cancer detection by using supplemental three-dimensional (3D) automated breast (AB) ultrasonography (US) with screening mammography versus screening mammography alone in asymptomatic women with dense breasts.
Materials And Methods: Institutional review board approval and written informed consent were obtained for this HIPAA-compliant study. The SomoInsight Study was an observational, multicenter study conducted between 2009 and 2011.
Background: Ipratropium and albuterol, combined in a single formulation, is widely used as three to four times daily maintenance therapy in COPD. This trial compared tiotropium, once daily, as a potential alternative to patients already taking the ipratropium/albuterol combination.
Methods: 676 patients with moderate to very severe stable COPD (mean FEV(1)=39% of predicted) maintained on ipratropium/albuterol were randomized to receive over an 84 day period either tiotropium (18 mcg) each morning, or continue with ipratropium (26 mcg)/albuterol (206 mcg), 2 actuations 4 times daily, using a parallel group, double-blind, double-dummy design.
Article Synopsis
- - Nebulized formoterol fumarate (FFIS) is a long-acting bronchodilator alternative for COPD patients who struggle with handheld devices, showing significant bronchodilation effects within 5 minutes of administration.
- - In a 12-week trial with 351 COPD subjects, FFIS significantly improved lung function (FEV1) and quality of life scores compared to placebo, with no signs of tolerance development.
- - FFIS had a comparable safety and efficacy profile to another inhaled treatment (Foradil Aerolizer), with the most common side effects being dry mouth, nausea, and insomnia.
Introduction: Ipratropium bromide (IB) is an established and effective first-line maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). A new IB metered-dose inhaler (MDI) using hydrofluoroalkane 134a propellant (IB HFA) has been developed as an alternative to the MDI containing chlorofluorocarbon (IB CFC).
Objective: To compare the long-term safety and efficacy of IB HFA and IB CFC in patients with COPD.